Nevro Corp (NYSE:NVRO), a medical device company specializing in spinal cord stimulation (SCS) technology for chronic pain treatment, has recently undergone significant changes in its market ...

August 20, 2024 — 01:04 pm EDT Written by Zacks Equity Research for Zacks -> Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge.

Nevro Corp.'s shares hit fresh lows after revenue guidance reset, reflecting stagnant growth and substantial losses. Learn more about NVRO stock here.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is ...

Nevro Stock Performance Shares of NVRO stock opened at $5.85 on Monday. Nevro Corp. has a 12 month low of $3.17 and a 12 month high of $11.65. The company has a debt-to-equity ratio of 0.67, a ...

Shares of NVRO stock opened at $5.85 on Tuesday. The company has a 50 day moving average of $5.78 and a 200-day moving average of $4.99. Nevro has a 12-month low of $3.17 and a 12-month high of ...

REDWOOD CITY, Calif., Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

Based on Nevro Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $104.16 million and a GAAP net loss of $19.58 million. In comparison ...

Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism, led by a solid third-quarter 2023 performance and continued ...

Estimate Trend Nevro witnessed a negative estimate revision trend for 2021. In the past 90 days, the Zacks Consensus Estimate for its loss per share has widened from $3.77 to $3.79.